RepliCel Life Sciences Inc (TSXV:RP)
RepliCel is a regenerative medicine company developing autologous cell therapies that address diseases caused by a deficit of healthy cells required for normal healing and function.
Xynomic, a US-Shanghai oncology pharma, announced that China, Spain and Poland authorities have approved Phase III trials of Xynomic’s abexinostat, in combination with pazopanib, in patients with renal cell carcinoma (RCC). Abexinostat is a novel HDAC inhibitor. Xynomic has already started the same trial in the US and South Korea. Xynomic in-licensed the drug in 2017 (see story), but did not disclose details of the transaction. The molecule was developed by Pharmacyclics, which was acquired by AbbVie in 2015.
Source: China Biotoday